Where Will Marker Therapeutics Inc (MRKR) Stock Go Next After It Has Fallen 9.16% in a Week?

Overall market sentiment has been down on Marker Therapeutics Inc (MRKR) stock lately. MRKR receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Marker Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MRKR!

See Full MRKR Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With MRKR Stock Today?

Marker Therapeutics Inc (MRKR) stock is trading at $4.86 as of 10:08 AM on Wednesday, Sep 27, a rise of $0.34, or 7.52% from the previous closing price of $4.52. The stock has traded between $4.84 and $5.02 so far today. Volume today is low. So far 4,890 shares have traded compared to average volume of 65,964 shares. To see InvestorsObserver's Sentiment Score for Marker Therapeutics Inc click here.

More About Marker Therapeutics Inc

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Click Here to get the full Stock Report for Marker Therapeutics Inc stock.